Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
BackgroundProgressive multifocal leukoencephalopathy (PML) is a severe complication of immunosuppressive therapies, especially of natalizumab in relapsing–remitting multiple sclerosis (MS). Metabolic changes within PML lesions have not yet been described in natalizumab-associated PML in MS patients....
Main Authors: | Ruth Schneider, Barbara Bellenberg, Robert Hoepner, Gisa Ellrichmann, Ralf Gold, Carsten Lukas |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-09-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00454/full |
Similar Items
-
Is There a (Host) Genetic Predisposition to Progressive Multifocal Leukoencephalopathy?
by: Eli eHatchwell
Published: (2015-05-01) -
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: risk reduction, management and possibilities for subsequent immunoregulation
by: Natalia V. Khachanova, et al.
Published: (2019-12-01) -
Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review
by: Tulika Chatterjee, et al.
Published: (2022-01-01) -
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
by: Pilar Santiago-Setien, et al.
Published: (2023-02-01) -
Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature
by: Yinan Zhang, et al.
Published: (2018-07-01)